Engineering the stambomycin modular polyketide synthase yields 37-membered mini-stambomycins.

Fiche publication


Date publication

janvier 2022

Journal

Nature communications

Auteurs

Membres identifiés du Cancéropôle Est :
Dr JACOB Christophe, Pr WEISSMAN Kira


Tous les auteurs :
Su L, Hôtel L, Paris C, Chepkirui C, Brachmann AO, Piel J, Jacob C, Aigle B, Weissman KJ

Résumé

The modular organization of the type I polyketide synthases (PKSs) would seem propitious for rational engineering of desirable analogous. However, despite decades of efforts, such experiments remain largely inefficient. Here, we combine multiple, state-of-the-art approaches to reprogram the stambomycin PKS by deleting seven internal modules. One system produces the target 37-membered mini-stambomycin metabolites - a reduction in chain length of 14 carbons relative to the 51-membered parental compounds - but also substantial quantities of shunt metabolites. Our data also support an unprecedented off-loading mechanism of such stalled intermediates involving the C-terminal thioesterase domain of the PKS. The mini-stambomycin yields are reduced relative to wild type, likely reflecting the poor tolerance of the modules downstream of the modified interfaces to the non-native substrates. Overall, we identify factors contributing to the productivity of engineered whole assembly lines, but our findings also highlight the need for further research to increase production titers.

Référence

Nat Commun. 2022 Jan 26;13(1):515